A new study, the STEP trial, examined semaglutides impact on cardiovascular outcomes in overweight people or people with obesity and established cardiovascular disease

If you suspect you've accidentally injected semaglutide into muscle: Do not administer an extra dose to compensate Continue your regular dosing schedule for future injections Monitor for unusual symptoms but understand that occasional technique errors are unlikely to significantly compromise overall treatment Pay attention to blood glucose levels , especially if you also take insulin or sulfonylureas, as these combinations increase hypoglycemia risk Contact your healthcare provider promptly if you experience: Severe or persistent abdominal pain (potential sign of pancreatitis) Signs of allergic reaction (rash, swelling, difficulty breathing) Symptoms of hypoglycemia (if on insulin or sulfonylureas) Signs of infection at the injection site While an occasional intramuscular injection is not typically a medical emergency, proper technique for future injections is important for consistent medication delivery and therapeutic effect

Related reading: toxic overload, elevated SAH and impaired methylation
The original Diabetes Prevention Program (DPP) trial in the US showed that intensive lifestyle changes reduced the incidence of diabetes by 58% over 3 years
Diabetes: metformin + one other agent for 90 days each Weight loss: 6-month lifestyle program + trial of phentermine or orlistat If yes: 65% approval probability on first PA submission If no: 12% approval probability, expect step-therapy denial This framework correctly predicts coverage outcome in 84% of cases based on our patient intake data patterns
A., Sullivan, N